PHP193 A Systematic Comparision of Iqwig Recommendations and G-Ba Decisions In The Amnog Process In Germany  by Vollmer, L et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A547
It is often assumed that the assessment by the SMC influences subsequent local 
recommendations on the funding and use of medicines in England. This research 
tests that hypothesis. Methods: Research was based on 86 medicines assessed 
by the SMC in 2012 and 2013, of which 56 were not reviewed by NICE. A sample of 
five local assessment groups in England was identified. From these we found a total 
of 53 recommendations relating to medicines not reviewed by NICE, of which 27 
were published subsequent to the SMC assessment. Results: Only around half 
(51%) of local assessments in England were published subsequent to SMC assess-
ments, so could potentially have been influenced. Of these recommendations 
two-thirds (18) were consistent with the SMC verdict, and one third (9) differed. 
Detailed analysis revealed additional factors. Several of the medicines in the sam-
ple were recommended by NICE on the basis of evidence summaries or in clinical 
guidelines. This advice, although not mandatory, appears from our sample to have 
been followed. Also some medicines not recommended by SMC were subject to 
specialised commissioning, the responsibility of NHS England rather than local 
commissioners. ConClusions: There is some consistency between assessments 
of new medicines in Scotland and England (as might be expected given that the 
evidence and decision criteria are broadly similar) but there are also significant dif-
ferences. It appears English advisory bodies make their decisions independently of 
SMC recommendations, and often earlier. Other differences, such as NICE evidence 
summaries and Specialised Commissioning in England, further reduce the influ-
ence of Scottish decisions.
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Regulations of tHe geRman DRug maRket
Friedmann B, Schwarz R, Freiberg M, Wilschke J, Meyer H
Quintiles Commercial, Mannheim, Germany
objeCtives: The framework specifications on pharmaceuticals (Rahmenvorgaben 
Arzneimittel) by the National Association of Statutory Health Insurance-Accredited 
Physicians (KBV) and the Statutory Health Insurance Scheme (GKV-Spitzenverband) 
are annually redefined. These specifications (Rahmenvorgaben) are binding for 
the 17 subnational drug agreements (Arzneimittelvereinbarungen) and target 
agreements (Zielvereinbarungen). They include quotas for lead compounds and 
prescription quotas. Individual subnational districts (KV Gebiete) set local drug 
specifications and quotas. These guide the prescription behavior. The objective of 
the analysis is to identify differences between the subnational regions regarding 
target agreements and resulting impacts. The analysis focuses also on the shift from 
innovative biologics to biosimilar products. Methods: The 17 subnational drug 
target agreements (Zielvereinbarungen) are analyzed regarding their differences/ 
specialities and their regulatory effect on the prescription of pharmaceutical classes 
e.g. anti-diabetic, anti-hypertensives, and the biosimilar proportion. Additionally 
the rapid prescription information of the SHI (GKV-Arzneimittel-Schnellinformation 
= GAmSi-data) and local regulation instruments are reviewed. Results: The 17 tar-
get agreements (Zielvereinbarungen) for the 15 defined classes of pharmaceuticals 
result in different quota fulfillment. An example is erythropoetin with a quantita-
tive quota range from 20% to 63%. The qualitative regulatory actions regarding the 
switch of biologics (Erythropoetin, Somatropin, Filgrastim, TNF alpha-blocker) to 
biosimilars vary from no regulation to recommendation or even priority prescrip-
tion. The additional defined subnational target agreements (Zielvereinbarungen) 
include targets on diabetes test strips, biosimilar quotas, individual substances or 
product-classes and can be individually adapted for the different physician spe-
cialties. ConClusions: In addition to the federal regulation system the German 
pharmaceutical market is fragmented in 17 subnational areas leading to different 
treatment behavior depending on the relevant subnational target agreements and 
the defined quotas. This analysis shows the wide variety of the subnational target 
agreements for different drug classes. They are not uniform and on a qualitative 
basis they even can exceed the determined federal targets.
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objeCtives: Since the introduction of AMNOG more than 100 IQWiG recommenda-
tions and G-BA decisions on the early benefit assessment have been published. In 
various assessments, the IQWiG recommendation and the related G-BA decision differ 
in terms of argumentation and result. In this study, these differences were systemati-
cally analyzed in order to draw conclusions for further proceedings. Methods: Data 
of all published IQWiG recommendations and G-BA decisions were standardized and 
transferred into the Prismaccess database. In a systematic analysis, major differ-
ences between the recommendations and decisions were quantitatively assessed. 
All documents of the identified decisions where differences were observed were 
then compared qualitatively. Results: In several aspects, major differences were 
found between IQWiG recommendations and G-BA decisions in approximately 25% 
of all cases. On the subgroup level, it was observed in at least n= 10 cases that the 
G-BA tends to use a broader definition of subgroups in its decisions than used in the 
IQWiG dossiers, (e.g. Telaprevir). In terms of the extent of the additional benefit, 17 
differences between IQWiG and G-BA decisions were registered, while mostly G-BA 
tend to evaluate better than IQWiG. In the probability of the additional benefit also 
some differences were observed. This can be explained by the opportunity to provide 
additional/new evidence during the oral hearing, which may influence the decision 
positively. Some proceedings were identified that took another way, as intended by 
the legislature: for example with Cobicistat, an incomplete paperwork was handed 
in, to achieve at least the price of the ACT. Still accepted by the G-BA, it is obvious 
that this should not be the normal case. ConClusions: In an early stage, G-BA 
consultations might be helpful clarifying subgroups-requirements. In the process, 
the oral hearing was identified as important instrument to supplement the required 
data and to correct uncertain issues from the dossier.
rules to calculate the price of branded drugs. Typically there is no negotiation 
between manufacturers and the IPR body. In the context of the German AMNOG 
price negotiations and the role of Germany as a key reference country, there is 
dearth of evidence on the international impact of the AMNOG law. Our objective 
was to evaluate the potential impact. Methods: An IRP tool (Orange) was used 
to simulate scenarios of price agreements for a new branded drug between the 
German Head Association of the Statutory Health Insurance Companies and the 
manufacturer. The impact of the price agreement on other countries was evalu-
ated based on the existing IRP rules as defined in the Orange tool. All prices were 
initially set at 100 euro to limit the impact to Germany only. Results: A 50% 
price drop in Germany, for example, would lead to a range of reductions across 
the world. The largest impact in Europe would be in France, Romania, Russia, 
Slovenia and Luxembourg (50% decrease) followed by Norway, Greece (17%) and 
the Netherlands (13%). Switzerland, Ireland, Denmark and Austria would be only 
marginally impacted. In contrast, with a price increase in Germany of 25% a limited 
impact in other countries was observed. Such an increase would lead to 6% price 
rise in the Netherlands, 4% in Switzerland, 3% in Ireland and Denmark, and a 1% 
increase in Austria. ConClusions: Price negotiations in Germany could poten-
tially impact the price of new branded therapies in numerous other countries. 
Ongoing downward pressure on pharmaceutical prices could ultimately have a 
negative impact on innovation and drug development in Europe.
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ultRa oRPHan anD canceR DRug PRicing tRenDs in tHe us anD tHe uk
Aggarwal S1, Topaloglu H1, Kumar S2
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, 
USA
objeCtives: Both ultra orphan and cancer drugs are premium priced therapies 
with high annual per patient costs. The local legislation and reimbursement 
mechanisms have had significant impact on pricing trends for these therapies. 
The objectives of this analysis were to compare the price differential for ultra 
orphan and cancer drugs in the US and the UK, and understand the impact of 
local reimbursement mechanisms. Methods: A set of 22 drugs (10 ultra orphan 
and 12 cancer drugs) was selected based on their availability in the US and the UK. 
The 2014 AWP, WAC and net prices were obtained for all 22 drugs. All UK prices 
were converted to USD. Primary discussions with ex-payer and policy experts 
were conducted to understand the basis and implication of the price differen-
tials. Results: For ten selected ultra orphan drugs, the median WAC price pre-
mium for the US compared to the UK net price was 10%. For 12 selected cancer 
drugs the median WAC price premium for the US compared to the UK net price 
was 106% (based on AWP the premiums were 29% and 149%, respectively). Eight 
out of 10 ultra orphan and 12 out of 12 cancer drugs were higher priced in the US 
compared to the UK. Primary discussions with experts suggest the role of legisla-
tion for coverage of cancer drugs in the US and special coverage of rare disease 
products in the UK and reimbursement mechanisms (use of cost effectiveness 
driven HTAs in the UK and the use of co-pay in the US) as primary drivers of high 
price differential for cancer drugs versus ultra orphan therapies. ConClusions: 
The local reimbursement mechanisms are major drivers of price differential for 
ultra orphan and cancer drugs in the US and the UK.
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Discount DistRiBution analysis of oRiginal meDicines wHicH Has no 
geneRics in tuRkey
Tuna E1, Yenilmez FB1, Atikeler K1, Kockaya G2
1Hacettepe University, Ankara, Turkey, 2Health Economics and Policy Association, ANKARA, 
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objeCtives: Pharmaceutical industry continues to grow and drug prices are a bur-
den for countries. Reference price system is assumed that such a practice concern-
ing medicines will lead to a decrease in medicine expenditures as medicine prices 
decrease. The objectives of this analysis to determine the distribution of discount 
of original medicines which has no generics from the reimbursement agency per-
spective in Turkey. Methods: In the analysis,“Detailed Price List” data published 
on the website of the Ministry of Health’s Turkish Medicines and Medical Devices 
Agency(TMMDA) and “Annex 4-A Funded Medicines List” data published by Social 
Security Institution(SSI) were used. The lists were merged using the Excel software 
and generic medicine including genericized original medicines with different pric-
ing and payment conditions compared to original medicines with no generics and 
other specific medicines such as blood products,enteral nutrition products, etc. and 
specific conditions such as medicines with no reimbursement were excluded. The 
analysis was made with a total of 568 original medicines with no generic. Ex-factory 
prices were used in the analysis. The reference prices of all original medicines 
(100%)are calculated by multiplying their actual reference price values with the 
periodic Euro value in the price list used in Turkey. Results: A comparison between 
ex-factory prices in TL and actual reference prices in TL revealed that 42.6% of the 
medicines had the same price,while 57.4% had a different price.The distribution of 
discount rates applied by SSI for 370 original medicines with a 41% discount rate 
and 99 original medicines with a 32.5% discount rate were found. ConClusions: 
In this analysis the mandatory discount rate for original drugs of 41% discount 
is mostly implemented by SSI. In rare cases, higher or lower discount rate can be 
applied. This is compatible with the implementation of the original drug reimburse-
ment policy rules. However, further analysis should be done to obtaining more 
detailed information.
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imPact of assessments of new meDicines By tHe smc in englanD
Furniss J1, Panciera D2, Roibu C2
1GfK NOP Ltd, Melton Mowbray, UK, 2GfK UK Ltd, London, UK
objeCtives: The Scottish Medicines Consortium (SMC), unlike the National 
Institute for Health and Care Excellence in England, assesses all new medicines. 
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PRO evidence is paramount. Adoption of PRO data by national and international can-
cer guidelines is key for centralized markets. Literature review findings corroborated 
with payer interviews indicated that inclusion of PRO data for crizotinib was crucial 
to achieving a price premium in Germany, with additional benefit based on PRO data 
on symptoms and quality of life. ConClusions: There is growing recognition that 
the patient perspective is important in market access decision making in central-
ized markets and PRO data can be a key differentiator among therapeutic options.
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stReamlining tHe access Decision PRocess foR geRman Patients to 
Receive ReimBuRseD tReatments in anotHeR euRoPean union memBeR 
state
Kumar A1, Siskind A1, Gupta S2
1ZS Associates, London, UK, 2ZS Associates, Gurgaon, India
objeCtives: The European Union Directive (2011/24/EU) requires member states 
to establish pathways that enable patients to receive reimbursed treatment in 
another European Union country. These cross-border access pathways are becom-
ing increasingly relevant for highly specialised medical technologies such as proton 
beam therapy and gene therapy, which are delivered by only a handful of provid-
ers across Europe. The objectives of our study were to understand how approvals 
for reimbursed cross-border treatments in the context of highly specialised treat-
ments work in Germany, and to identify any barriers and practical steps to overcome 
these. Methods: We have investigated the case-by-case access decision pathway for 
German patients to receive highly specialised treatments in another country using 
secondary research, and awareness surveys with Health Care Practitioners. Results: 
We found the biggest barrier for cross-border treatment access are delays in the 
case-by-case approval process caused by (a) low awareness of cross-border access 
pathways amongst Health Care Practitioners, (b) the lack of well-defined guidelines 
on how to make the case for medical need, and (c) case-by-case reimbursement 
negotiations between the sickness fund and the treatment provider in the other 
country. ConClusions: To overcome these barriers we suggest manufacturers 
and/or the provider of the highly specialised treatment to engage with the MDK 
(Medizinischer Dienst der Krankenkassen - Medical Service of Health Insurance) to 
define the requirements of the patient dossier, and to agree a checklist to bring a 
degree of objectivity in to medical need assessment. Additionally, we suggest work-
ing with the major sickness funds to negotiate a reimbursement rate, in advance 
of the first patient being identified for the treatment. Establishing these processes 
and making Health Care Practitioners aware of them would reduce approval times 
for German patients to access highly specialised treatments delivered in another 
EU member state.
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nuB status – an analysis comPaRing Results of 2015 vs. 2014 - leaDing 
tHeRaPeutic aReas confiRmeD
Freiberg M, Friedmann B, Schalk E, Schwarz R
Quintiles Commercial, Mannheim, Germany
objeCtives: Within the German hospital landscape (in-patient), NUBs (Neue 
Untersuchungs- und Behandlungsmethoden) [new treatment and examination 
methods] represent a key method to achieve reimbursement for new, cost-intensive 
drugs, medical products or procedures. NUBs are paid on top of hospital budget and 
hence represent additional funding for hospitals. The objective of this analysis was 
to provide an overview on the proportion of drugs (vs. methods, medicinal prod-
ucts) and their respective indications for 2015 and compare these to the results 
of 2014. Methods: The German DRG database issued by the InEK (Institute for 
Hospital Remuneration System) is used to analyse NUB subgroups sorted according 
to key therapeutic indications for the years 2015 and 2014. Additionally the number 
of NUB 1 (positive status) products that went through the AMNOG process up to 
June 2015 is being analysed. Results: Out of 670 NUB submissions 159 (24%) are 
classified as drugs in 2015. Results for the year 2014 were 618 NUB submissions with 
133 (22%) drugs. The analysis also compares proportion of drugs in different NUB 
classification levels for 2015 and 2014 (NUB 1-4). Leading therapeutic areas are iden-
tified. Chances to grant a successfull NUB 1 status approval for drugs and procedures 
are examined. Out of 56 drugs that were given NUB 1 status, 29 (52%) had passed 
through AMNOG process until June 2015. 43 drugs with NUB status 1 and 24 (55%) 
that had passed the early benefit assessment by June 2014 (55%). ConClusions: 
Drug applications are more likely than procedures to be given NUB 1 status and 
thereby initiate reimbursement negotiations with the SHI. Results of 2015 confirm 
the findings for 2014. Oncology products showed the highest success rates in two 
consecutive years. Oncology products are often high priced therapies and use the 
NUB system to enter the G-DRG system for future reimbursement.
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aRe vaccinations Really DiffeRent to PHaRmaceuticals witH ResPect 
to maRket access in geRmany?
Droeschel D1, Vollmer L1, Krone FA2, Walzer S1
1MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, 2State University 
Baden-Wuerttemberg, Loerrach, Germany
objeCtives: Although AMNOG was introduced to reorganize the medicine prod-
ucts market, it is not applicable for vaccines. Immunization in Germany is organized 
de-centrally under the responsibility of the social health insurance. The aim of this 
study was to analyze the market access route and compare that to the AMNOG pro-
cess. Methods: The market access route was analyzed systematically and mapped 
the pathway by identifying key processes, stakeholders, applicable regulations and 
laws, pricing and negotiation setting and supply chain conditions. Results: Based 
on the results of the systematic analysis we could ascertain specifics for the vaccina-
tion market. The Standing Committee on Immunisation (STIKO) by the Robert Koch 
Institute decides regularly on vaccination recommendations. Vaccinations are obliga-
tory provisions of the SHIs and based on a regulation within with the G-BA defines 
details and requirements, type and scope. Further, SHIs can provide optional benefits 
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PHaRmacoeconomic guiDeline foR Positive DRug list aPPlication 
PuRPoses imPlementeD in BulgaRia
Savova A1, Stoimenova A1, Manova M1, Zidarova B2, Petrova G1, Danchev N2
1Medical University Sofia, Faculty of Pharmacy, Sofia, Bulgaria, 2National Council of prices and 
reimbursement of medicinal products, Sofia, Bulgaria
objeCtives: The economic evaluation of new medicines is substantial for allo-
cating the limited healthcare budgets. In Bulgaria, according to the legislation for 
pricing and reimbursement of medicinal products applied to be included in the 
Positive Drug List, pharmacoeconomic assessment shall be performed according 
to the criteria based on efficacy, therapeutic effectiveness, safety, and pharmaco-
economic parameters. However, until recently there were no detailed guidelines 
for applicants available and in April 2015 methodological recommendations were 
implemented. The objective of methodological recommendations is to achieve 
optimal assessment of candidate medicinal products applying for the PDL inclu-
sion. Methods: A working group of representatives from National Council for 
Pricing and Reimbursement of medicinal products, Bulgarian Drug Agency, and 
experts from academia developed a guideline, following the good practices of other 
countries to provide standardized approach to economic evaluation of medicinal 
products in Bulgaria. Results: The guideline is structured in five sections including 
requirements for provided data for efficacy, therapeutic effectiveness and safety, as 
well as pharmacoeconomic parameters. Applicants need to prepare their applica-
tions according to the requirements provided by these methodological recommen-
dations.There should be a clear and unambiguous conclusion about the benefits 
of the medicinal product, subject to evaluation over the existing alternatives, the 
clinical significance and its place in therapy. If there is an economic evaluations 
conducted with a candidate medicinal product for other health systems or pub-
lished by HTA agencies in Europe it is necessary to be provided with respective 
motives for positive or negative decision. ConClusions: The implemented phar-
macoeconomic guideline will facilitate the appraisal of medicinal products based 
on objective and transparent information which will allow the decision makers to 
justify the reimbursement of new medicinal products based on scientific evidences 
and available resources.
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DiffeRences Between tHe efficacy of BiosimilaRs anD oRiginatoRs - 
analysis anD imPlications foR tHe cost-effectiveness-analysis fRom 
a PayeRs PeRsPective
Bierbaum M1, Haffer A2, Bierbaum ME3
1HS Aalen, Nürnberg, Germany, 2FAU Erlangen-Nürnberg, Nürnberg, Germany, 3BERSERCON, 
Nürnberg, Germany
objeCtives: Before biosimilars entered the market the decision making process 
for payers regarding generics was straightforward. As the active pharmaceutical 
ingredient was the same molecule, a cheaper generic version would always be 
more cost-effective than its original counterpart. This changed with the upcoming 
of biosimilars of erythropoiesis-stimulating agents. Several publications pointed 
to differences in effectiveness between original and generic versions. Therefore, 
a payer no longer could solely rely on price comparison, but had to factor the effi-
cacy difference when he was trying to limit drug expenditures. The question arose 
whether the efficacy gaps are only observed in erythropoetins or are general for all 
biologicals. Methods: We searched the scientific literature and the EMA database 
for comparative studies for all currently approved biosimilars in Europe. Data for the 
quantity needed to reach a given therapeutic effect, was extracted. Subsequently 
the prices from a German payers perspective were taken from official tariffs and 
applied to the price-efficacy-equation. Results: Until Q1/2015 19 biosimilars were 
granted market authorization in Europe. Analysis showed that erythropoetins are 
the only ones with relevant efficacy differences between originator and generic 
version. All other biosimilar agents were equivalent to the reference drug according 
to EMA standards. Price information was not available for three drugs currently not 
marketed in Germany. For all other drugs the prices of the generic versions were 
significantly below the originator version resulting in a better price-efficacy-ratio 
for the biosimilars. ConClusions: Except for erythropoetin biosimilars no differ-
ences in efficacy could be observed in the analyzed study data. Therefore it seems 
legitimate for payers to limit their view to the price in the price-efficacy-ratio when 
making reimbursement decisions regarding biosimilars.
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influence of Patient-RePoRteD outcomes (PRo) on maRket access 
Decisions in maRkets witH centRalizeD HealtHcaRe systems
Hogue S1, Brogan AP1, DeMuro C1, Barrett A1, D’Alessio D2, Bal V2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharmaceuticals Corporation, 
East Hanover, NJ, USA
objeCtives: To understand how PRO data from clinical trials are utilized in market 
access decision making in oncology and other disease areas in markets with central-
ized healthcare systems. Methods: PubMed/MEDLINE, Embase, ISPOR databases, 
and regulatory and HTA websites for the EMA, the UK, France, and Germany were 
searched to identify PRO data included in regulatory and HTA submissions of four 
oncology drugs: bevacizumab, pemetrexed, sunitinib, and crizotinib. One-on-one 
interviews were conducted with 10 payers from different countries with centralized 
healthcare systems in 2014. An online assessment was conducted (December 8, 2014, 
to March 4, 2015) with 5 completed surveys (China, France, Germany, Taiwan, the UK) 
and 2 partially completed surveys (Australia and South Korea) by payers from the 
RTI Health Solutions Global Payer Advisory Panel. Results: Reviews of HTA and 
reimbursement decisions indicate that HTA bodies have varying levels of familiarity 
and confidence in PRO data. All 10 payers indicated that it is worthwhile to collect PRO 
data in clinical trials for oncology, particularly in phase 3 and postmarketing studies. 
Payers speculated that PRO data will increase in importance over the next 5-10 years 
and could be a key differentiator for new therapies. Payers offered little differentiation 
in the importance of PRO data by cancer type. Payers indicated that the quality of the 
